

# Larynx and Base of Tongue 2024

NAACCR Monthly Webinar

October 3, 2024

## Case #1

71-year-old Caucasian male with history of hypertension, hyperlipidemia, diabetes mellitus, who presented with a four-week period of worsening dysphonia and hoarseness. Patient was a smoker until five years ago (1 PPD x 25 years). Social etoh (wine with dinner). Father diagnosed with prostate cancer at age 74.

On exam, no palpable masses or tenderness on neck. No palpable lymphadenopathy. Fiberoptic exam revealed a left vocal cord white lesion. No other lesions noted. Biopsy recommended.

### Imaging:

**3/25/24 @ ABC Hospital: CT Neck=** No definite true vocal cords, laryngeal or paralaryngeal lesions. No neck mass lesion or enlarged lymph nodes.

**3/28/24 @ ABC Hospital: PET/CT=** FDG avid left true vocal cord mass extending to the anterior commissure, SUV max 10.8. No other sites of abnormal FDG uptake.

### Pathology:

**4/3/24 @ ABC Hospital:** Left true vocal cord biopsy= squamous cell carcinoma, moderately differentiated.

### Treatment:

RT Completion Summary @ ABC Hospital:

Txt Site	Energy	Dose/fx	# of fx	Total dose (cGy)	Start date	End date
Glottis	6X/IMRT	2.25	28	6300	4/21/24	6/2/24

## CASE 1

Tumor Description		Grade			
Primary Site		Clinical		Tumor Size Summary	
Laterality		Pathological			
Histology		Post Therapy (yc)			
Behavior		Post Therapy (yp)			
AJCC Staging Items					
Clinical T		Pathological T		ycT	ypT
cT Suffix		pT Suffix		ycT Suffix	ypT Suffix
Clinical N		Pathological N		ycN	ypN
cN Suffix		pN Suffix		ycN Suffix	ypN Suffix
Clinical M		Pathological M		yc M	ypM
Stage Group		Stage Group		Stage Group	Stage Group
SS2018/EOD					
Summary Stage 2018					
Extent of Disease					
EOD Primary Tumor		EOD Regional Nodes		EOD Mets	
Regional Nodes Positive					
Regional Nodes Examined					
SSDI					
ENE Clinical		LN Size of Mets			
ENE Pathological					
Surgery Codes			Systemic Therapy Codes		
Diagnostic Staging Procedure			Chemotherapy		
Surgical Procedure of Primary Site			Hormone Therapy		
Scope of RLN Node Surgery			Immunotherapy		
Radiation					
Phase		1	2	3	1 2 3
Primary Treatment Volume					Dose Per fraction
Draining LN					Fractions
Modality					Total Dose
EB Planning Technique					

## Case #2

67-year-old female with h/o CKD, hypertension, hyperlipidemia, who presented to her primary care physician with a palpable right neck mass. Patients also report neck discomfort and swelling. Patient is a current 1PPD smoker. Negative family history. Social etoh (beer on weekends).

### Imaging:

**1/8/24 @ XYZ Hospital: CT neck/soft tissue=** Enlarged 3.0 cm right level IIA lymph node concerning for metastatic adenopathy. No other enlarged lymph nodes. No abnormal nodular or mass like enhancement within the visualized aerodigestive tract.

**1/12/24 @ XYZ Hospital: PET/CT=** FDG uptake co-registering with the enlarged RT level IIA lymph node (SUV max 20.2) noted on previous CT scan. Asymmetric FDG uptake at right root of tongue. No other sites of FDG uptake to suggest metastatic disease.

### Pathology:

**1/15/24 @ XXX Hospital:** FNA of right neck level II lymph node= metastatic squamous cell carcinoma.

**HPV in situ hybridization:** HPV low risk (6/11) negative. HPV high risk (16/18/33) positive.

**EBER ISH** probe negative.

**P16** Patchy expression of p16 by immunohistochemistry.

### Treatment:

RT Completion Summary @ **XXX Hospital:**

Txt Site	Energy	Dose/fx	# of fx	Total dose (cGy)	Start date	End date
BOT/H&N	6X/Arc	200	35	7,000	2/1/24	3/20/24

**2/1/24 @ XXX Hospital:** Single agent cisplatin concurrent with EBRT.

**CASE 2**

Tumor Description		Grade			
Primary Site		Clinical		Tumor Size Summary	
Laterality		Pathological			
Histology		Post Therapy (yc)			
Behavior		Post Therapy (yp)			
Schema Discriminator 2: Oropharyngeal p16			1-p16 negative		
<b>AJCC Staging Items (correct answer to scenario 2)</b>					
Clinical T		Pathological T		ycT	
cT Suffix		pT Suffix		ycT Suffix	
Clinical N		Pathological N		ycN	
cN Suffix		pN Suffix		ycN Suffix	
Clinical M		Pathological M		yc M	
Stage Group		Stage Group		Stage Group	
<b>SS2018/EOD</b>					
<b>Extent of Disease</b>					
EOD Primary Tumor		EOD Regional Nodes		EOD Mets	
<b>AJCC Staging Items</b>					
<i>Changes to scenario above: 1.5 cm tumor confined to the base of the tongue and IHC test not done (histology 8086)</i>					
Clinical T		Pathological T		ycT	
cT Suffix		pT Suffix		ycT Suffix	
Clinical N		Pathological N		ycN	
cN Suffix		pN Suffix		ycN Suffix	
Clinical M		Pathological M		yc M	
Stage Group		Stage Group		Stage Group	
<b>SS2018/EOD</b>					
<b>Extent of Disease</b>					
EOD Primary Tumor		EOD Regional Nodes		EOD Mets	

<b>AJCC Staging Items</b>										
Changes to scenario above: 1.5 cm tumor confined to the base of the tongue p16+										
<b>Clinical T</b>		<b>Pathological T</b>			<b>ycT</b>		<b>ypT</b>			
<b>cT Suffix</b>		<b>pT Suffix</b>			<b>ycT Suffix</b>		<b>ypT Suffix</b>			
<b>Clinical N</b>		<b>Pathological N</b>			<b>ycN</b>		<b>ypN</b>			
<b>cN Suffix</b>		<b>pN Suffix</b>			<b>ycN Suffix</b>		<b>ypN Suffix</b>			
<b>Clinical M</b>		<b>Pathological M</b>			<b>yc M</b>		<b>ypM</b>			
<b>Stage Group</b>		<b>Stage Group</b>			<b>Stage Group</b>		<b>Stage Group</b>			
<b>SS2018/EOD</b>										
<b>Summary Stage 2018</b>										
<b>Extent of Disease</b>										
<b>EOD Primary Tumor</b>				<b>EOD Regional Nodes</b>			<b>EOD Mets</b>			
<b>Regional Nodes Positive</b>										
<b>Regional Nodes Examined</b>										
<b>SSDI</b>										
<b>ENE Clinical</b>		<b>LN Size of Mets</b>								
<b>ENE Pathological</b>		<b>SEER SSF 1</b>								
<b>Surgery Codes</b>					<b>Systemic Therapy Codes</b>					
<b>Diagnostic Staging Procedure</b>							<b>Chemotherapy</b>			
<b>Surgical Procedure of Primary Site</b>							<b>Hormone Therapy</b>			
<b>Scope of RLN Node Surgery</b>							<b>Immunotherapy</b>			
<b>Radiation</b>										
<b>Phase</b>		1	2	3				1	2	3
<b>Primary Treatment Volume</b>							<b>Dose Per fraction</b>			
<b>Draining LN</b>							<b>Fractions</b>			
<b>Modality</b>							<b>Total Dose</b>			
<b>EB Planning Technique</b>										

### **Case #3**

69-year-old Caucasian male with h/o thyroid nodule, hypertension, GERD, who presented with a palpable “lump” at the angle of the jaw on the right side, with associated TMJ symptoms. Patient also reported intermittent difficulty with swallowing. Denies weight loss or SOB. Nonsmoker. No alcohol use. Father w/ non-melanoma skin cancer (BCC).

#### **Imaging:**

**3/28/24 @ XXX Hospital: CT Neck/soft tissue=** 1.5 cm lobulated enhancing RT base of tongue mass noted, consistent with neoplasm. Mass extends to the level of the vallecular. Bilateral cervical chain metastatic lymphadenopathy with prominent RT level II 1.9 cm nodal mass.

**4/5/24 @ XXX Hospital: PET/CT=** Abnormal hypermetabolic activity in RT tongue base mass (SUV max 20.1), consistent with biologic tumor activity. Conglomerate RT level II cervical lymph nodes (SUV max 21.2) and left cervical level II subcentimeter lymph nodes (SUV max 5.8). No other sites of abnormal FDG uptake.

#### **Pathology:**

**4/2/24 @ XXX Hospital: Right-sided neck level II lymph node US-guided FNA=** positive for malignant cells, necrotic neoplastic cells, consistent with metastatic squamous cell carcinoma.

Flow cytometry analysis non-contributory due to too few viable lymphocytes.

IHC stain for p16 strongly positive.

#### **Treatment:**

##### **RT Completion Summary @ YYY Hospital**

<b>Txt Site</b>	<b>Energy</b>	<b>Dose/fx</b>	<b># of fx</b>	<b>Total dose (cGy)</b>	<b>Start date</b>	<b>End date</b>
<b>Oropharynx/Neck</b>	6X/VMAT	200	35	7,000	4/24/24	6/19/24

Cisplatin administered concurrently with EBRT @ YYY Hospital.

## CASE 3

Tumor Description		Grade			
Primary Site		Clinical		Tumor Size Summary	
Laterality		Pathological			
Histology		Post Therapy (yc)			
Behavior		Post Therapy (yp)			
AJCC Staging Items					
Clinical T		Pathological T		ycT	
cT Suffix		pT Suffix		ycT Suffix	
Clinical N		Pathological N		ycN	
cN Suffix		pN Suffix		ycN Suffix	
Clinical M		Pathological M		yc M	
Stage Group		Stage Group		Stage Group	
SS2018/EOD					
Summary Stage 2018					
Extent of Disease					
EOD Primary Tumor		EOD Regional Nodes		EOD Mets	

Regional Nodes Positive					
Regional Nodes Examined					
SSDI					
ENE Clinical		LN Size of Mets			
ENE Pathological		SEER SSF 1			
Surgery Codes			Systemic Therapy Codes		
Diagnostic Staging Procedure			Chemotherapy		
Surgical Procedure of Primary Site			Hormone Therapy		
Scope of RLN Node Surgery			Immunotherapy		
Radiation					
Phase		1	2	3	
Primary Treatment Volume					Dose Per fraction
Draining LN					Fractions
Modality					Total Dose
EB Planning Technique					